Silenseed

Silenseed is a clinical-stage biopharmaceutical company developing cancer drugs and delivery systems based on proprietary RNA interference (RNAi) technology, designed to effectively penetrate and treat malignant solid tumors. The company’s novel drugs, used in conjunction with the new delivery system LODER™ (LOcal Drug EluteR), have the potential to become one of the most effective treatments for solid tumor cancers. Current diseases in the company’s pipeline include pancreatic cancer, prostate cancer, and certain brain cancers.